Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00043368 · ClinicalTrials.gov registry record · Phase 2

PF-3512676 (CPG 7909) Injection For Patients Who Completed An Oncology Study Using PF-3512676 (CPG 7909)

A Phase 2 study of Melanoma and Carcinoma, Non-Small Cell Lung, sponsored by Pfizer.

Completed
Registry status
Phase 2
Development phase
31
Enrollment target
20
Study locations

NCT00043368 is a Phase 2 study of Melanoma and Carcinoma, Non-Small Cell Lung that has completed, run by Pfizer. The registered enrollment target is 31 participants, below the 706-participant average among 266 other Melanoma trials with a reported enrollment target (96% lower). The trial reports 20 study locations across 4 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00043368, a Phase 2 study of Melanoma and Carcinoma, Non-Small Cell Lung, has completed, sponsored by Pfizer.

COMPLETED
Registry status
Phase 2
Development phase
31 participants
Enrollment target
20
Study locations

Study Summary

This protocol allows patients who completed Coley oncology studies using PF-3512676 (CPG 7909) Injection to continue receiving the treatment until disease progression.

Conditions Studied

Melanoma Carcinoma, Non-Small Cell Lung Breast Neoplasms Carcinoma, Renal Cell Lymphoma, T-Cell

Interventions

  • DRUG PF-3512676

Study Locations (20)

Florida

  • Pfizer Investigational Site - Bonita Springs
  • Pfizer Investigational Site - Bradenton
  • Pfizer Investigational Site - Cape Coral
  • Pfizer Investigational Site - Fort Myers
  • Pfizer Investigational Site - Fort Myers
  • Pfizer Investigational Site - Naples
  • Pfizer Investigational Site - Plantation
  • Pfizer Investigational Site - Port Charlotte
  • Pfizer Investigational Site - Sarasota
  • Pfizer Investigational Site - Venice
  • Pfizer Investigational Site - Venice

California

  • Pfizer Investigational Site - Berkely
  • Pfizer Investigational Site - Gilroy
  • Pfizer Investigational Site - Hollister
  • Pfizer Investigational Site - Los Angeles
  • Pfizer Investigational Site - Los Angeles
  • Pfizer Investigational Site - Palm Springs
  • Pfizer Investigational Site - Stanford

Connecticut

  • Pfizer Investigational Site - New Haven

Illinois

  • Pfizer Investigational Site - Chicago

Trial Details

FieldValue
Enrollment Target 31 participants
Start Date 2002-09
Est. Completion 2007-06
Phase Phase 2

Sponsor

Pfizer

1,845 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00043368

The ClinicalTrials.gov registry entry for NCT00043368 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 31 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 706-participant average among 266 other Melanoma trials with a reported enrollment target (96% lower). The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.

The record links to 5 conditions, with Melanoma appearing as the primary indexed condition, and to 1 intervention - of which PF-3512676 is the first listed.

NCT00043368 reports 20 study locations spanning 4 distinct geographic areas - top geographies include Florida, California, Connecticut.

Frequently Asked Questions

What is clinical trial NCT00043368 about?

NCT00043368 is a clinical study titled "PF-3512676 (CPG 7909) Injection For Patients Who Completed An Oncology Study Using PF-3512676 (CPG 7909)". This protocol allows patients who completed Coley oncology studies using PF-3512676 (CPG 7909) Injection to continue receiving the treatment until disease progression.

What is the current status of trial NCT00043368?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 31 participants. The study started on 2002-09. Estimated completion is 2007-06.

What conditions does trial NCT00043368 study?

This clinical trial studies the following conditions: Melanoma, Carcinoma, Non-Small Cell Lung, Breast Neoplasms, Carcinoma, Renal Cell, Lymphoma, T-Cell.

What interventions are being tested in trial NCT00043368?

The interventions under investigation include: PF-3512676 (DRUG).

Who is sponsoring clinical trial NCT00043368?

This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00043368 being conducted?

This trial has 20 study locations across California, Connecticut, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Melanoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Melanoma

All registered trials for this condition

Carcinoma, Non-Small Cell Lung

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.